{"organizations": [], "uuid": "c988411bf25ede9eeeda9eed0994ae43c9dc427a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180213.html", "section_title": "Archive News &amp; Video for Tuesday, 13 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-verona-pharma-expects-to-report-to/brief-verona-pharma-expects-to-report-top-line-data-from-phase-2b-trial-of-nebulized-rpl554-early-in-q2-idUSASB0C5E1", "country": "US", "domain_rank": 408, "title": "Verona Pharma Expects To Report Top-Line Data From Phase 2b Trial Of Nebulized RPl554​ Early In Q2", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.125, "site_type": "news", "published": "2018-02-13T20:48:00.000+02:00", "replies_count": 0, "uuid": "c988411bf25ede9eeeda9eed0994ae43c9dc427a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-verona-pharma-expects-to-report-to/brief-verona-pharma-expects-to-report-top-line-data-from-phase-2b-trial-of-nebulized-rpl554-early-in-q2-idUSASB0C5E1", "ord_in_thread": 0, "title": "Verona Pharma Expects To Report Top-Line Data From Phase 2b Trial Of Nebulized RPl554​ Early In Q2", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "verona pharma", "sentiment": "negative"}, {"name": "verona pharma plc", "sentiment": "negative"}, {"name": "pharma plc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 13 (Reuters) - Verona Pharma Plc:\n* VERONA PHARMA PROVIDES CLINICAL DEVELOPMENT UPDATE * VERONA PHARMA PLC - ‍ANTICIPATES REPORTING TOP-LINE DATA FROM ITS PHASE 2B TRIAL EARLY IN Q2 OF 2018 FOR NEBULIZED RPL554​\n* VERONA PHARMA PLC - ‍ANTICIPATES REPORTING TOP-LINE DATA FROM ITS PHASE 2A TRIAL IN LATE Q1 OF 2018 FOR CLINICAL TRIAL OF RPL554 FOR CYSTIC FIBROSIS​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-13T20:48:00.000+02:00", "crawled": "2018-02-14T12:51:20.029+02:00", "highlightTitle": ""}